Oncobiologics and inVentiv Health have formed a global, strategic partnership for clinical development of biosimilar assets initially with a probable expansion to new molecules.
The biosimilar assets include generic versions of Humira, Rituxan, Avastin, Herceptin and Erbitux indicated for their respective cancer and immune-disease indications.
Oncobiologics founder and CEO Pankaj Mohan said, "After an exhaustive global review of potential partners, we selected the broad-scale inVentiv platform as an important differentiator for our program as this partnership spans both clinical and bioanalytical development as well as commercialization of our biosimilar assets."
Under the partnership, inVentiv Health will carry out clinical studies as well as provide corresponding bioanalytical support for the trials.
The partnership will be further broadened to include inVentiv's significant commercialization capabilities in select countries for the commercialization of the assets.
inVentiv Health Clinical president Ray Hill said, "By joining their fully-integrated CMC capabilities with inVentiv's broad clinical and commercial expertise, we are creating a venture that is truly greater than the sum of its parts."